0 results available. Select is focused ,type to refine list, press Down to open the menu,
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The compan...
The following section summarizes insights on Inozyme Pharma Inc's Damodaran's Industry Cost of Equity:
We've identified the following companies as similar to Inozyme Pharma Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
| Name | Ticker | Damodaran's Industry Cost of Equity |
|---|---|---|
| Inozyme Pharma Inc | NASDAQGS:INZY | - |
| Ainos Inc | OTCPK:AIMD | - |
| Caredx Inc | NASDAQGM:CDNA | - |
| Windtree Therapeutics Inc | NASDAQCM:WINT | - |
| Olema Pharmaceuticals Inc | NASDAQGS:OLMA | - |
| Vaccinex Inc | OTCPK:VCNX | - |
| Monte Rosa Therapeutics Inc | NASDAQGS:GLUE | - |
| Aura Biosciences Inc | NASDAQGM:AURA | - |
| Coherus BioSciences Inc | NASDAQGM:CHRS | - |
| Fate Therapeutics Inc | NASDAQGM:FATE | - |
| Larimar Therapeutics Inc | NASDAQGM:LRMR | - |
| Healthcare | SECTOR:HLTH.US | 9.1% |
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Damodaran's Industry Cost of Equity in the valuation category include:
A general benchmark for the cost of equity in an industry based on research by Professor Damodaran at New York University, Stern.
The chart above depicts the distribution of damodaran's industry cost of equity for companies operating in the Healthcare sector in the Developed economic region. Over 60 companies were considered in this analysis, and 68 had meaningful values. The average damodaran's industry cost of equity of companies in the sector is 9.1% with a standard deviation of 0.8%.
Inozyme Pharma Inc's Damodaran's Industry Cost of Equity of - is significantly outside the interquartile range and is excluded from the distribution. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 68 |
| Included Constituents | 68 |
| Min | 7.2% |
| Max | 10.0% |
| Median | 9.1% |
| Mean | 9.1% |
| Standard Deviation | 0.8% |
You can find companies with similar damodaran's industry cost of equity using this stock screener.